New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
05:56 EDTSWY, EXELStocks with implied volatility below IV index mean; SWY EXEL
Stocks with implied volatility below IV index mean; Safeway (SWY) 12, Exelixis (EXEL) 89 according to iVolatility.
News For SWY;EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
16:23 EDTSWYSupervalu to provide distribution, transition services to Haggen
Subscribe for More Information
16:08 EDTSWYSafeway, Albertsons confirm agreements to sell 168 stores to four buyers
AB Acquisition LLC and Safeway (SWY) announced that they have entered into agreements, subject to approval by the Federal Trade Commission to sell 168 stores across eight states to four buyers: Associated Food Stores will purchase eight stores in Montana and Wyoming; Associated Wholesale Grocers / Minyards will purchase 12 stores in Texas; SUPERVALU (SVU) will purchase two stores in Washington; and Haggen will purchase 146 stores across Arizona, California, Nevada, Oregon and Washington. Divestiture of these stores is being undertaken in order to secure FTC clearance of the companies' proposed merger, which was announced in March and is expected to close in January 2015. The purchase agreements with the four buyers are all subject to approval by the FTC. Under the terms of the purchase agreements, the buyers will acquire the stores, equipment and inventory, and they intend to hire most, if not all, of the store employees upon the closing of the purchase of the stores.
December 15, 2014
05:24 EDTEXELExelixis announces Genentech files NDA for cobimetinib, vemurafenib combination
Exelixis (EXEL) announced its collaborator Genentech, a member of the Roche Group (RHHBY), has completed the filing of its New Drug Application, or NDA, with the FDA for cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib for previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation. Cobimetinib has received Fast Track designation by the FDA. Roche submitted a Marketing Authorization Application for the combination to the European Medicines Agency in September of this year. The NDA is based on data from the coBRIM trial, a phase 3 pivotal trial conducted by Genentech in 495 patients with BRAF V600 mutation-positive unresectable locally advanced or metastatic melanoma.
December 11, 2014
07:28 EDTEXELCBI to hold a summit
2nd Specialty Data Optimization Summit is being held in Philadelphia on December 11.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use